
VYNE Therapeutics Inc. (NASDAQ:VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).
FMX 114 is evaluated in the Phase 2a four weeks segment study for the treatment in patients suffering from atopic dermatitis compared to vehicle control.